Polaris Group commences phased submission of a BLA for ADI-PEG 20 to the U.S. FDA to manage Malignant Pleural Mesothelioma.

Inhibiting the downstream ERK can block cell signal transduction, and ERK inhibitors can overcome tumor cells' resistance to upstream target inhibitors. This gives them broader application prospects in clinical settings.

Astellas and Pfizer's XTANDI® gets FDA approval for update, following fast-tracked review and EMBARK study results.

On 11 Dec 2023, the updated clinical results of Axatilimab at 3 different doses in patients with Chronic Graft-Versus-Host Disease (AGAVE-201) will be reported in 2023 ASH.

Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.

The application of DPP-4 inhibitors brings new hope to the treatment of Type 2 Diabetes.

argenx reveals green light from European Commission for the subcutaneous usage of VYVGART® (efgartigimod alfa) in treating Generalized Myasthenia Gravis.

The development of dihydrofolate reductase inhibitors has always been challenging. dihydrofolate reductase inhibitors have therapeutic applications in cancer, malaria, and protozoan infections.

The latest clinical findings of KT-333 will be unveiled at the 2023 ASH Congress, setting the stage for subsequent investigations.

DHODH inhibitors are drugs inhibiting the enzyme DHODH crucial in DNA and RNA production, disrupting cell growth.

The first patient was treated with ALE.C04 in a Phase 1/2 study by Alentis Therapeutics, aimed at treating Head and Neck Squamous Cell Carcinoma (HNSCC).

EZH2 inhibition impacts both tumor cells and TME Gaining a deeper understanding of the multiple effects of EZH2i in these patients could potentially aid in predicting clinical responses.